Navidea Biopharmaceuticals Price Prediction
NAVBDelisted Stock | USD 0.08 0 2.63% |
Oversold Vs Overbought
52
Oversold | Overbought |
Navidea Biopharmaceutica stock price prediction is an act of determining the future value of Navidea Biopharmaceutica shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Navidea Biopharmaceutica's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Navidea Biopharmaceutica and does not consider all of the tangible or intangible factors available from Navidea Biopharmaceutica's fundamental data. We analyze noise-free headlines and recent hype associated with Navidea Biopharmaceuticals, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether pink sheet price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Navidea Biopharmaceutica based on different types of headlines from major news networks to social media. The Navidea stock price prediction module provides an analysis of price elasticity to changes in media outlook on Navidea Biopharmaceutica over a specific investment horizon. Using Navidea Biopharmaceutica hype-based prediction, you can estimate the value of Navidea Biopharmaceuticals from the perspective of Navidea Biopharmaceutica response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Navidea Biopharmaceutica. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Navidea Biopharmaceutica to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Navidea because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Navidea Biopharmaceutica after-hype prediction price | USD 0.08 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Navidea |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Navidea Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Navidea Biopharmaceutica After-Hype Price Prediction Density Analysis
As far as predicting the price of Navidea Biopharmaceutica at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Navidea Biopharmaceutica or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Navidea Biopharmaceutica, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Navidea Biopharmaceutica Estimiated After-Hype Price Volatility
In the context of predicting Navidea Biopharmaceutica's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Navidea Biopharmaceutica's historical news coverage. Navidea Biopharmaceutica's after-hype downside and upside margins for the prediction period are 0.07 and 0.08, respectively. We have considered Navidea Biopharmaceutica's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Navidea Biopharmaceutica is very steady at this time. Analysis and calculation of next after-hype price of Navidea Biopharmaceutica is based on 3 months time horizon.
Navidea Biopharmaceutica Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Navidea Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Navidea Biopharmaceutica backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Navidea Biopharmaceutica, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 15 Events / Month | 3 Events / Month | In about 15 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.08 | 0.08 | 2.70 |
|
Navidea Biopharmaceutica Hype Timeline
Navidea Biopharmaceutica is now traded for 0.08. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Navidea is anticipated to increase in value after the next headline, with the price projected to jump to 0.08 or above. The average volatility of media hype impact on the company the price is insignificant. The price jump on the next news is estimated to be 2.7%, whereas the daily expected return is now at 0.0%. The volatility of related hype on Navidea Biopharmaceutica is about 0.0%, with the expected price after the next announcement by competition of 0.08. The company currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Given the investment horizon of 90 days the next anticipated press release will be in about 15 days. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.Navidea Biopharmaceutica Related Hype Analysis
Having access to credible news sources related to Navidea Biopharmaceutica's direct competition is more important than ever and may enhance your ability to predict Navidea Biopharmaceutica's future price movements. Getting to know how Navidea Biopharmaceutica's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Navidea Biopharmaceutica may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
NBY | NovaBay Pharmaceuticals | (0.01) | 7 per month | 0.00 | (0.15) | 7.69 | (9.85) | 29.12 | |
ONCS | OncoSec Medical | (0.07) | 2 per month | 0.00 | (0.24) | 27.24 | (35.71) | 167.71 | |
CYCC | Cyclacel Pharmaceuticals | 0.04 | 4 per month | 6.89 | 0.06 | 17.37 | (9.93) | 58.93 | |
TENX | Tenax Therapeutics | (0.34) | 9 per month | 0.00 | (0.1) | 9.56 | (9.91) | 95.75 | |
ABIO | ARCA Biopharma | 0.34 | 7 per month | 1.63 | 0.12 | 4.33 | (4.13) | 95.29 |
Navidea Biopharmaceutica Additional Predictive Modules
Most predictive techniques to examine Navidea price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Navidea using various technical indicators. When you analyze Navidea charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Navidea Biopharmaceutica Predictive Indicators
The successful prediction of Navidea Biopharmaceutica stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Navidea Biopharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Navidea Biopharmaceutica based on analysis of Navidea Biopharmaceutica hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Navidea Biopharmaceutica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Navidea Biopharmaceutica's related companies. Story Coverage note for Navidea Biopharmaceutica
The number of cover stories for Navidea Biopharmaceutica depends on current market conditions and Navidea Biopharmaceutica's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Navidea Biopharmaceutica is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Navidea Biopharmaceutica's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Navidea Biopharmaceutica Short Properties
Navidea Biopharmaceutica's future price predictability will typically decrease when Navidea Biopharmaceutica's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Navidea Biopharmaceuticals often depends not only on the future outlook of the potential Navidea Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Navidea Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 29.3 M | |
Cash And Short Term Investments | 2 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |